eloralintide vs petrelintide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: Amylin receptor · full Obesity pipeline

eloralintide

Developed by Eli Lilly

Phase 3 in Obesitypeptide
Reliable signal

NCT06230523 · Phase 2 · completed

Randomized, double-blind, placebo-controlled phase 2 in obesity and overweight (263 participants). Week-48 body-weight reductions ranged from 9.4% to 20.1% across eloralintide doses versus 0.4% on placebo, a separation many times larger than the reported error margins; percent change in body weight is the accepted registrational endpoint in obesity.

Next expected readout: December 2026 · NCT07738614 (registry estimate)

Reported efficacy

Percent Change From Baseline in Body Weight at Week 48 (Baseline, Week 48): Body weight, percent change from baseline at Week 48: eloralintide 1 mg -9.4%, 3 mg -12.4%, 6 mg -17.6%, 9 mg -20.1%, 6/9 mg -19.9% and 3/6/9 mg -16.5% vs placebo -0.4%. (met)

Result source: NCT06230523

petrelintide

Developed by Zealand Pharma and partners

Phase 3 in Obesitypeptide
Partial signal

NCT06662539 · Phase 2 · completed

The study was randomized and double-blind, used matching placebo, and enrolled 493 participants. Its primary clinical endpoint was change in body weight, but the outcome comparison is not yet available because results have not been posted.

Next expected readout: November 2027 · NCT07589686 (registry estimate)

Reported efficacy

Percent change from baseline in body weight to Week 28 (From Baseline (Day 1) to Week 28): Primary endpoint met: statistically significant weight reduction vs placebo at week 28 in all five dose arms; up to 10.7% mean reduction at week 42 vs 1.7% with placebo (ZUPREME-1, 2026-03-05). (met)

Result source: NCT06662539

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointeloralintidepetrelintide
Body weight, % change-20.1% vs -0.4%−19.7 vs placebo9 mg · wk 48 · n 54NCT06230523
5 other results
  • -19.9% vs -0.4% 6/9 mg · wk 48 · n 24 · Phase 2 · primary NCT06230523
  • -17.6% vs -0.4% 6 mg · wk 48 · n 28 · Phase 2 · primary NCT06230523
  • -12.4% vs -0.4% 3 mg · wk 48 · n 24 · Phase 2 · primary NCT06230523
  • -9.4% vs -0.4% 1 mg · wk 48 · n 28 · Phase 2 · primary NCT06230523
  • -16.5% vs -0.4% 3/6/9 mg · wk 48 · n 52 · Phase 2 · primary NCT06230523
—Trial running · NCT07843485
Weight loss of 5% or more92.7% vs 31.2%+61.5 vs placebo9 mg · wk 48 · n 54NCT06230523
5 other results
  • 97.5% vs 31.2% 6/9 mg · wk 48 · n 24 · Phase 2 · secondary NCT06230523
  • 85.0% vs 31.2% 6 mg · wk 48 · n 28 · Phase 2 · secondary NCT06230523
  • 87.1% vs 31.2% 3 mg · wk 48 · n 24 · Phase 2 · secondary NCT06230523
  • 71.5% vs 31.2% 1 mg · wk 48 · n 28 · Phase 2 · secondary NCT06230523
  • 90.8% vs 31.2% 3/6/9 mg · wk 48 · n 52 · Phase 2 · secondary NCT06230523
—Trial running · NCT07843485
Weight loss of 10% or more82.3% vs 12.8%+69.5 vs placebo9 mg · wk 48 · n 54NCT06230523
5 other results
  • 91.1% vs 12.8% 6/9 mg · wk 48 · n 24 · Phase 2 · secondary NCT06230523
  • 76.6% vs 12.8% 6 mg · wk 48 · n 28 · Phase 2 · secondary NCT06230523
  • 60.5% vs 12.8% 3 mg · wk 48 · n 24 · Phase 2 · secondary NCT06230523
  • 53.3% vs 12.8% 1 mg · wk 48 · n 28 · Phase 2 · secondary NCT06230523
  • 79.2% vs 12.8% 3/6/9 mg · wk 48 · n 52 · Phase 2 · secondary NCT06230523
—Trial running · NCT07843485
Waist circumference, change (cm)—Trial running · NCT07321886—Trial running · NCT07843485

Body weight, % change

eloralintide
-20.1% vs -0.4%−19.7 vs placebo9 mg · wk 48 · n 54NCT06230523
5 other results
  • -19.9% vs -0.4% 6/9 mg · wk 48 · n 24 · Phase 2 · primary NCT06230523
  • -17.6% vs -0.4% 6 mg · wk 48 · n 28 · Phase 2 · primary NCT06230523
  • -12.4% vs -0.4% 3 mg · wk 48 · n 24 · Phase 2 · primary NCT06230523
  • -9.4% vs -0.4% 1 mg · wk 48 · n 28 · Phase 2 · primary NCT06230523
  • -16.5% vs -0.4% 3/6/9 mg · wk 48 · n 52 · Phase 2 · primary NCT06230523
petrelintide
—Trial running · NCT07843485

Weight loss of 5% or more

eloralintide
92.7% vs 31.2%+61.5 vs placebo9 mg · wk 48 · n 54NCT06230523
5 other results
  • 97.5% vs 31.2% 6/9 mg · wk 48 · n 24 · Phase 2 · secondary NCT06230523
  • 85.0% vs 31.2% 6 mg · wk 48 · n 28 · Phase 2 · secondary NCT06230523
  • 87.1% vs 31.2% 3 mg · wk 48 · n 24 · Phase 2 · secondary NCT06230523
  • 71.5% vs 31.2% 1 mg · wk 48 · n 28 · Phase 2 · secondary NCT06230523
  • 90.8% vs 31.2% 3/6/9 mg · wk 48 · n 52 · Phase 2 · secondary NCT06230523
petrelintide
—Trial running · NCT07843485

Weight loss of 10% or more

eloralintide
82.3% vs 12.8%+69.5 vs placebo9 mg · wk 48 · n 54NCT06230523
5 other results
  • 91.1% vs 12.8% 6/9 mg · wk 48 · n 24 · Phase 2 · secondary NCT06230523
  • 76.6% vs 12.8% 6 mg · wk 48 · n 28 · Phase 2 · secondary NCT06230523
  • 60.5% vs 12.8% 3 mg · wk 48 · n 24 · Phase 2 · secondary NCT06230523
  • 53.3% vs 12.8% 1 mg · wk 48 · n 28 · Phase 2 · secondary NCT06230523
  • 79.2% vs 12.8% 3/6/9 mg · wk 48 · n 52 · Phase 2 · secondary NCT06230523
petrelintide
—Trial running · NCT07843485

Waist circumference, change (cm)

eloralintide
—Trial running · NCT07321886
petrelintide
—Trial running · NCT07843485
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

petrelintide
Primary endpoint met: statistically significant weight reduction vs placebo at week 28 in all five dose arms; up to 10.7% mean reduction at week 42 vs 1.7% with placebo (ZUPREME-1, 2026-03-05). NCT06662539 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. eloralintide: 4 of 4 rows · petrelintide: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metriceloralintide
Dropout rate
20.8%6/9 mga
NCT06230523 · Phase 2
show 5 more results
11.1%9 mg
NCT06230523 · Phase 2
25%6 mg
NCT06230523 · Phase 2
20.8%3 mg
NCT06230523 · Phase 2
46.4%1 mg
NCT06230523 · Phase 2
11.5%3/6/9 mg
NCT06230523 · Phase 2
Discontinued due to AEs
0%6/9 mga
NCT06230523 · Phase 2
show 5 more results
1.9%9 mg
NCT06230523 · Phase 2
3.6%6 mg
NCT06230523 · Phase 2
0%3 mg
NCT06230523 · Phase 2
7.1%1 mg
NCT06230523 · Phase 2
3.8%3/6/9 mg
NCT06230523 · Phase 2
Serious AEs
8.3%6/9 mga
NCT06230523 · Phase 2
show 5 more results
5.6%9 mg
NCT06230523 · Phase 2
3.6%6 mg
NCT06230523 · Phase 2
4.2%3 mg
NCT06230523 · Phase 2
10.7%1 mg
NCT06230523 · Phase 2
1.9%3/6/9 mg
NCT06230523 · Phase 2
Most frequent reported AEs
6/9 mga
nausea 54.2% (placebo 13.2%)
fatigue 45.8% (placebo 11.3%)
upper respiratory tract infection 20.8% (placebo 11.3%)
NCT06230523 · Phase 2
show 5 more results
9 mg
fatigue 42.6% (placebo 11.3%)
nausea 33.3% (placebo 13.2%)
constipation 24.1% (placebo 5.7%)
NCT06230523 · Phase 2
6 mg
nausea 64.3% (placebo 13.2%)
diarrhoea 35.7% (placebo 9.4%)
fatigue 28.6% (placebo 11.3%)
NCT06230523 · Phase 2
3 mg
constipation 16.7% (placebo 5.7%)
arthralgia 12.5% (placebo 5.7%)
fatigue 12.5% (placebo 11.3%)
NCT06230523 · Phase 2
1 mg
benign prostatic hyperplasia 14.3% (placebo 15.4%)
constipation 14.3% (placebo 5.7%)
covid-19 14.3% (placebo 3.8%)
NCT06230523 · Phase 2
3/6/9 mg
nausea 25% (placebo 13.2%)
fatigue 21.2% (placebo 11.3%)
diarrhoea 17.3% (placebo 9.4%)
NCT06230523 · Phase 2

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

eloralintide

Weight -20.1% (n=54) vs -0.4% (n=53) placebo @ 48wk9 mg
percent change · % of baseline
NCT06230523 · Phase 2
show 5 more results
-19.9% (n=24) vs -0.4% (n=53) placebo @ 48wk6/9 mg
NCT06230523 · Phase 2
-17.6% (n=28) vs -0.4% (n=53) placebo @ 48wk6 mg
NCT06230523 · Phase 2
-12.4% (n=24) vs -0.4% (n=53) placebo @ 48wk3 mg
NCT06230523 · Phase 2
-9.4% (n=28) vs -0.4% (n=53) placebo @ 48wk1 mg
NCT06230523 · Phase 2
-16.5% (n=52) vs -0.4% (n=53) placebo @ 48wk3/6/9 mg
NCT06230523 · Phase 2
Weight -21.3 vs -0.2 placebo kg @ 48wk9 mg
absolute change · kg
NCT06230523 · Phase 2
show 5 more results
-21 vs -0.2 placebo kg @ 48wk6/9 mg
NCT06230523 · Phase 2
-18.7 vs -0.2 placebo kg @ 48wk6 mg
NCT06230523 · Phase 2
-13.3 vs -0.2 placebo kg @ 48wk3 mg
NCT06230523 · Phase 2
-10.2 vs -0.2 placebo kg @ 48wk1 mg
NCT06230523 · Phase 2
-18 vs -0.2 placebo kg @ 48wk3/6/9 mg
NCT06230523 · Phase 2
Weight Loss 5% 92.72% (n=54) vs 31.21% (n=53) placebo @ 48wk9 mg
responder rate · % of participants
NCT06230523 · Phase 2
show 5 more results
97.5% (n=24) vs 31.21% (n=53) placebo @ 48wk6/9 mg
NCT06230523 · Phase 2
84.99% (n=28) vs 31.21% (n=53) placebo @ 48wk6 mg
NCT06230523 · Phase 2
87.12% (n=24) vs 31.21% (n=53) placebo @ 48wk3 mg
NCT06230523 · Phase 2
71.55% (n=28) vs 31.21% (n=53) placebo @ 48wk1 mg
NCT06230523 · Phase 2
90.8% (n=52) vs 31.21% (n=53) placebo @ 48wk3/6/9 mg
NCT06230523 · Phase 2
Weight Loss 10% 82.32% (n=54) vs 12.85% (n=53) placebo @ 48wk9 mg
responder rate · % of participants
NCT06230523 · Phase 2
show 5 more results
91.13% (n=24) vs 12.85% (n=53) placebo @ 48wk6/9 mg
NCT06230523 · Phase 2
76.57% (n=28) vs 12.85% (n=53) placebo @ 48wk6 mg
NCT06230523 · Phase 2
60.45% (n=24) vs 12.85% (n=53) placebo @ 48wk3 mg
NCT06230523 · Phase 2
53.25% (n=28) vs 12.85% (n=53) placebo @ 48wk1 mg
NCT06230523 · Phase 2
79.24% (n=52) vs 12.85% (n=53) placebo @ 48wk3/6/9 mg
NCT06230523 · Phase 2
BMI -7.7 vs -0.2 placebo kg @ 48wk9 mg
absolute change · kg
NCT06230523 · Phase 2
show 5 more results
-7.8 vs -0.2 placebo kg @ 48wk6/9 mg
NCT06230523 · Phase 2
-6.7 vs -0.2 placebo kg @ 48wk6 mg
NCT06230523 · Phase 2
-4.7 vs -0.2 placebo kg @ 48wk3 mg
NCT06230523 · Phase 2
-3.7 vs -0.2 placebo kg @ 48wk1 mg
NCT06230523 · Phase 2
-6.4 vs -0.2 placebo kg @ 48wk3/6/9 mg
NCT06230523 · Phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: eloralintide's landscape · petrelintide's landscape